RALDH2 expression in primary human cells and transformed human cell lines
| Cell type . | Origin . | Stimuli . | RALDH2 . |
|---|---|---|---|
| Primary human cells | |||
| Basophils | Blood | + IL-3 | + |
| Eosinophils | Blood | ± IL-3, IL-5, GM-CSF | − |
| Neutrophils | Blood | ± GM-CSF | − |
| pDCs | Blood | ± IL-3 | − |
| mDCs | Blood | ± LPS | − |
| Monocytes | Blood | ± IFN-γ, GM-CSF, M-CSF, IL-4, IL-13, IL-3 | − |
| Naive T cells | Blood | ± Anti-CD3/anti-CD28 | − |
| Memory T cells | Blood | ± Anti-CD3/anti-CD28 | − |
| Th1/Th2 clones | Blood | ± Anti-CD3/anti-CD28 | − |
| NKT cells | Blood | ± OCH, aGalCer, PHA | − |
| B cells | Blood | − | − |
| Total PBMCs | Blood | ± IL-3 | − |
| Mast cells | Intestinal tissue | ± SCF | − |
| Embryonic cells | Meninges | − | + |
| Cell lines | Lineage | ||
| HEP-G2 | Human hepatocellular carcinoma | − | |
| K562 | Human chronic myeloid leukemia | (+)? | |
| GM-1 | Human histiocytic lymphoma | − | |
| Jurkat | Human T-cell leukemia | +* | |
| Molt-4 | Human T-cell leukemia | +† | |
| 721.221 | Human B lymphoblastoma | − | |
| HL60 | Human acute myeloid leukemia | − | |
| HL60/Bcr-Abl | HL60 transfected with Bcr-Abl | + | |
| HMC-1 | Human mast cell leukemia | − | |
| KU812 | Human chronic myeloid leukemia (basophilic) | − | |
| NK92 | Human natural killer lymphoma | − | |
| BEAS-2B | Human bronchial epithelium | − | |
| Cell type . | Origin . | Stimuli . | RALDH2 . |
|---|---|---|---|
| Primary human cells | |||
| Basophils | Blood | + IL-3 | + |
| Eosinophils | Blood | ± IL-3, IL-5, GM-CSF | − |
| Neutrophils | Blood | ± GM-CSF | − |
| pDCs | Blood | ± IL-3 | − |
| mDCs | Blood | ± LPS | − |
| Monocytes | Blood | ± IFN-γ, GM-CSF, M-CSF, IL-4, IL-13, IL-3 | − |
| Naive T cells | Blood | ± Anti-CD3/anti-CD28 | − |
| Memory T cells | Blood | ± Anti-CD3/anti-CD28 | − |
| Th1/Th2 clones | Blood | ± Anti-CD3/anti-CD28 | − |
| NKT cells | Blood | ± OCH, aGalCer, PHA | − |
| B cells | Blood | − | − |
| Total PBMCs | Blood | ± IL-3 | − |
| Mast cells | Intestinal tissue | ± SCF | − |
| Embryonic cells | Meninges | − | + |
| Cell lines | Lineage | ||
| HEP-G2 | Human hepatocellular carcinoma | − | |
| K562 | Human chronic myeloid leukemia | (+)? | |
| GM-1 | Human histiocytic lymphoma | − | |
| Jurkat | Human T-cell leukemia | +* | |
| Molt-4 | Human T-cell leukemia | +† | |
| 721.221 | Human B lymphoblastoma | − | |
| HL60 | Human acute myeloid leukemia | − | |
| HL60/Bcr-Abl | HL60 transfected with Bcr-Abl | + | |
| HMC-1 | Human mast cell leukemia | − | |
| KU812 | Human chronic myeloid leukemia (basophilic) | − | |
| NK92 | Human natural killer lymphoma | − | |
| BEAS-2B | Human bronchial epithelium | − | |
Isolated primary human blood cells were stimulated 24 to 72 hours with the stimuli indicated (for concentrations, see corresponding Western blots throughout the paper); MCs were cultured for up to 4 weeks. Cell lines were maintained under standard culture conditions. The presence or induction of RALDH2 protein was determined in cell extracts as analyzed by Western blotting using anti-RALDH2 antibody.
+ indicates clearly detected; (+)?, near detection limit; and −, undetectable. See Figures 1, 4, and S2 for original data.
Truncated transcript only.
Truncated and full-length transcript.